Impax, Teva settle with J&J, Alza over generic ADHD drug

Generic drug makers can launch version of Concerta in July 2013

HAYWARD, Calif. — Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

Impax Labs and Teva Pharmaceuticals USA had settled a patent infringement suit with Janssen Pharmaceuticals and Alza over Concerta (methylphenidate hydrochloride) extended-release tablets in the 18-mg, 27-mg, 36-mg and 54-mg strengths.

Under the agreement, Impax and Teva will be licensed to sell generic versions of the drug starting July 14, 2013. The two companies are pursuing a strategic alliance agreement with regard to the drug.

Branded and generic versions of Concerta had sales of about $1.2 billion during the 12-month period ended in July, according to Wolters Kluwer Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.